Reuters: Health
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
GSK sees breakthrough in shingles vaccine output in 2024
GSK sees breakthrough in shingles vaccine output in 2024
Reuters: Health
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
Reuters: Health
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment